The MUnich SArcopenia Registry (MUSAR) : Paving the way for increased visibility, more frequent diagnoses and innovative new treatment.

Abstract

Background: The consensus definition of sarcopenia enables a clear diagnostic algorithm. The syndrome can now also be coded in Germany (International Classification of Diseases 10, ICD-10 GM 62.50). Compared to the estimated prevalence it is still significantly underdiagnosed. Current treatment options include resistance training and a protein-rich diet, while pharmacological options are still missing.

Objective: The Munich Sarcopenia Registry (MUSAR) aims to raise awareness of the syndrome and affected individuals. Additionally, it seeks to gain insights into risk factors, causes and treatment approaches. This publication conducts an initial analysis of 90 patient datasets with varying degrees of sarcopenia and examines the cohort for key geriatric parameters.

Material and methods: Since 2018 patients from the geriatric clinic of the Ludwig Maximilians University Munich have been able to contribute their data to the registry. Sociodemographic, anthropometric, functional, and laboratory data are collected in a web-based registry.

Results: Compared to patients without sarcopenia, patients with sarcopenia are significantly older, have more comorbidities and show poorer functional performance as well as reduced quality of life.

Discussion: The results highlight the urgent need for further research and the development of new forms of treatment to improve the quality of life and independence of these patients. Challenges such as difficult recruitment complicate this endeavor. The MUSAR aims to minimize these issues and provides a valuable basis for generating extensive data through the systematic collection of patient data during hospital stays.